Bovie Medical Corporation — Form 10-Q Summary
Filing identity: The submitted filing is for Bovie Medical Corporation, not Apyx Medical Corp as stated in the request metadata. It covers the quarter and six months ended June 30, 2011; financial amounts below are in USD millions unless otherwise noted.
Business context and reporting period
Bovie manufactured and marketed electrosurgical devices, battery-operated cauteries, and other medical products. It sold mainly through distributors, with international sales representing 24.2% of first-half 2011 revenue, versus 21.7% a year earlier. The company said its business was generally not seasonal.
Financial performance and liquidity
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Revenue | $6.841 | $5.897 | $12.995 | $11.496 |
| Gross profit | $3.045 | $2.316 | $5.478 | $4.601 |
| Gross margin | 44.5% | 39.3% | 42.2% | 40.0% |
| Operating income (loss) | $0.549 | $(0.791) | $1.135 | $(1.123) |
| Net income (loss) | $0.429 | $0.056 | $0.921 | $(0.170) |
| Basic and diluted EPS | $0.02 | $0.00 | $0.05 | $(0.01) |
First-half operating cash flow was $2.217 million, compared with cash used of $0.333 million in the cash-flow statement for first-half 2010. Investing cash outflow was $0.261 million; financing cash outflow was $0.069 million. Cash increased to $5.714 million from $3.827 million at year-end 2010.
At June 30, 2011, total current assets were $16.380 million and current liabilities were $2.001 million; working capital was reported as $14.4 million. Debt included $3.670 million of industrial revenue bonds, of which $0.143 million was current, plus $0.112 million of long-term capital lease obligations. The $8 million revolving credit facility had no balance; reported borrowing availability was approximately $3.9 million, plus approximately $0.890 million under an equipment facility. The company reported compliance with credit covenants.
Material changes versus prior comparable period
- Revenue increased 16.0% in Q2 and 13.0% in the first half. Electrosurgical sales led growth, supported by generator demand and new coated-blade electrode sales. First-half international sales rose 26.1%, compared with 9.4% domestic growth.
- Gross margin improved, which management attributed mainly to a more favorable mix of higher-margin generators and disposable products, lower labor and material costs, and benefits from consolidating Canadian operations into Florida.
- First-half net income included a $0.750 million litigation-settlement gain. It also included a $0.248 million net gain from fair-value changes in liabilities; these items affect comparability with operating performance.
- First-half R&D expense fell 38.0% to $0.635 million, while SG&A fell 7.6% to $2.235 million. Management cited lower costs associated with the Canadian consolidation and reduced support for certain product lines.
Outlook, risks, contingencies, and unusual items
- No quantified earnings or revenue guidance was provided. Management expected cash on hand and operating cash flows to cover operating cash commitments for the next year and intended to fund continuing product development from operating cash flows.
- In July 2011, after quarter-end, RBC notified Bovie that it would not renew the letter of credit supporting the industrial revenue bonds when it expires in December 2011. Bovie said it was negotiating with another bank to take over the letter of credit.
- A March 2011 settlement with Salient Surgical Technologies and Medtronic required Bovie to exit the worldwide monopolar and bipolar saline-enhanced RF device business through February 2015. Bovie received $0.750 million, reserved approximately $0.087 million against affected inventory, and could not sell certain finished goods. Its Medtronic OEM generator agreement was to end December 31, 2011, with final deliveries in 2012; service obligations continue for five years.
- Litigation with former director Steven Livneh remained unresolved, including counterclaims against the company and its CEO and COO. The company stated that no potential loss was recorded because the outcome was uncertain. Other ordinary-course legal claims also remained subject to uncertainty.
- Customer concentration was material: the ten largest customers accounted for approximately 67% of first-half revenue, and one customer accounted for 14% of sales.
- Inventory was $7.215 million net of reserves, and the company identified inventory obsolescence and product demand as significant estimation risks. First-half inventory-obsolescence provision was $0.059 million.
Most important facts for investors to verify
- Confirm the filing entity and its relationship, if any, to Apyx Medical Corp; this document identifies Bovie Medical Corporation.
- Reconcile the cash-flow comparison: the financial statement reports first-half 2010 operating cash used of $0.333 million, while MD&A cites approximately $0.373 million.
- Track the replacement letter of credit for the industrial revenue bonds and any effects on bond terms, liquidity, or access to credit facilities.
- Assess the earnings contribution from the $0.750 million settlement and fair-value gains separately from recurring operating results.
- Monitor the end of the Medtronic OEM agreement, the saline-enhanced device business restriction, customer concentration, and the unresolved Livneh litigation.